2. Signaling Pathways
  3. Immunology/Inflammation
  4. PD-1/PD-L1

PD-1/PD-L1

PD-1/Programmed death-ligand 1

PD-1/PD-L1

Related Products

PDF 0.7 MB

Programmed death-1 (PD-1) is a cell surface receptor that functions as a T cell checkpoint and plays a central role in regulating T cell exhaustion. PD-1 is activated by the engagement of its ligands PDL-1 or PDL-2. PD-1 receptor delivers inhibitory checkpoint signals to activated T cells upon binding to its ligands PD-L1 and PD-L2 expressed on antigen-presenting cells and cancer cells, resulting in suppression of T-cell effector function and tumor immune evasion. Inhibiting the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway is an attractive strategy for tumor immunotherapy.

PD-1 is expressed on activated T cells, B cells, monocytes, dendritic cells (DCs), regulatory T cells (Tregs), and natural killer T cells (NKT). It is a member of a family of immunoglobulin domain (Ig) co-receptors that modify the outcome of activation of the T cell receptor by an antigen-presenting cell (APC) or infected target cell. PD-L1 is widely and constitutively expressed on both hematopoietic and nonhematopoietic cells; e.g., naive T and B cells, vascular endothelial cells, and pancreatic islet cells, whereas PD-L2 is exclusively and inducibly expressed on professional APCs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-148305
    PD-1/PD-L1-IN-28
    		Inhibitor
    PD-1/PD-L1-IN-28 (compound 3) is an immune checkpoint inhibitor of PD-1/PD-L1 signaling pathway (IC50=0.744 µM). PD-1/PD-L1-IN-28 shows good research potential in tumor immunity.
    PD-1/PD-L1-IN-28
  • HY-174424
    NPH16
    		Inhibitor
    NPH16 is an orally active PD-1/PD-L1 inhibitor with an IC50 of 24.4 nM. NPH16 can promote HepG2 cell apoptosis. NPH16 shows excellent in vivo antitumor efficacy and favorable pharmacokinetic properties. NPH16 can be used for the study of liver cancer.
    NPH16
  • HY-149617
    CYP51/PD-L1-IN-4
    		Inhibitor
    CYP51/PD-L1-IN-4 (compound 14a-2) is a potent dual-target (CYP51/PD-L1) inhibitor, with IC50 values of 0.17 and 0.021 μM, respectively. CYP51/PD-L1-IN-4 exhibits excellent antifungal and antidrug-resistant fungal activity in vitro. CYP51/PD-L1-IN-4 can be used for fungal infections research.
    CYP51/PD-L1-IN-4
  • HY-162519
    LZFPN-90
    		Inhibitor
    LZFPN-90 (LZ90) is a dual NAMPT/PD-L1 targeting compound. LZFPN-90 inhibits PD-1/PD-L1 interaction and NAMPT activity. LZFPN-90 inhibits cell growth in a NAMPT-dependent manner and blocks the cell cycle, subsequently inducing apoptosis. LZFPN-90 exerted target-dependent antitumor activities, affecting metabolic processes and the immune system.
    LZFPN-90
  • HY-P991345
    MEDI-0680
    		Inhibitor
    MEDI-0680 (AMP-514) is a human IgG4 monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. MEDI-0680 can be used in Diffuse Large B-Cell Lymphoma (DLBCL) research.
    MEDI-0680
  • HY-158052
    PD-1/PD-L1 antagonist 1
    		Antagonist
    PD-1/PD-L1 antagonist 1 (Compound A5) is an antagonist for programmed cell death-1 (PD-1) and programmed cell death ligand-1 (PD-L1) interaction, with an IC50 of 23.78 nM.
    PD-1/PD-L1 antagonist 1
  • HY-145773
    PD-1/PD-L1-IN-22
    		Inhibitor
    PD-1/PD-L1-IN-22 (Example 2) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-22 blocks PD-1/PD-L1 with the IC50 of 0.732 μM. PD-1/PD-L1-IN-22 can be used for the research of cancers, infectious diseases and autoimmune diseases.
    PD-1/PD-L1-IN-22
  • HY-145768
    PD-1/PD-L1-IN-18
    		Inhibitor
    PD-1/PD-L1-IN-18 (Compound L31) is a small-molecule inhibitor of the PD-1/PD-L1 protein-protein interaction. PD-1/PD-L1-IN-18 blocks PD-1/PD-L1 with the IC50 of 1.054 μM. Antitumor Activity.
    PD-1/PD-L1-IN-18
  • HY-120647
    BMS-1001
    		Inhibitor
    BMS-1001 is an orally active human PD-L1/PD-1 immune checkpoint inhibitor. BMS-1001 exhibits low-toxicity in cells. The IC50 value of BMS-1001 in a homogeneous time-resolved fluorescence (HTRF) binding assay is 2.25 nM.
    BMS-1001
  • HY-P10908
    H-20
    		Agonist
    H-20 is a PD-1 agonist. H-20 can be used in the research of chronic pain.
    H-20
  • HY-143305
    PD-1/PD-L1-IN-25
    		Inhibitor
    PD-1/PD-L1-IN-25 (compound D2) is an inhibitor of PD-1/PD-L1 interaction with an IC50 value of 16.17 nM. PD-1/PD-L1-IN-25 activates the antitumor immunity of T cells efficiently in PBMCs. PD-1/PD-L1-IN-25 can be used for the research of cancer.
    PD-1/PD-L1-IN-25
  • HY-161677
    PD-L1/CD-73-IN-1
    		Inhibitor
    PD-L1/CD-73-IN-1 (compound CC-5) is PD-L1/CD73 inhibitor with IC50 values of 6 nM and 0.773 μM to PD-L1 and CD73, respectively. PD-L1/CD-73-IN-1 inhibits tumor cell growth in vivo and in vitro.
    PD-L1/CD-73-IN-1
  • HY-174468
    dPDL1-4
    		Degrader
    dPDL1-4 is a potent and selective eHSPTAC eHSP90 PD-L1 degrader with DC50s of 7.77 μM and 6.52 μM in HeLa and B16F10 cells. dPDL1-4 bridges eHSP90 with the target protein, inducing lysosomal degradation. dPDL1-4 can degrade PD-L1 significantly and inhibits tumor growth. dPDL1-4 can be used for the study of cervical cancer and melanoma. ((Pink: eHSP90 ligand (HY-174476); Blue: PD-L1 ligand (HY-116274); Black: Linker (HY-W021787); HSP ligand + linker: HY-174799)).
    dPDL1-4
  • HY-144442
    PD-1/PD-L1-IN-15
    		Inhibitor
    PD-1/PD-L1-IN-15 (Compound M17) is a potent inhibitor of PD-1/PD-L1 with an IC50 value of 60.1 nM. PD-1/PD-L1-IN-15 has the potential for the research of tumor immunoresearch.
    PD-1/PD-L1-IN-15
  • HY-P991344
    AMP-224
    		Inhibitor
    AMP-224 is a fusion protein targeting PD-L2. AMP-224 specifically binds to PD-1 T cells (chronically stimulated/exhausted T cells). AMP-224 can be used in Colorectal cancer and Solid tumours research.
    AMP-224
  • HY-172601
    HDAC3-IN-7
    		Degrader
    HDAC3-IN-7 (Compound 8ae) is a selective HDAC3 inhibitor with an IC50 value of 311 nM. HDAC3-IN-7 degrades PD-L1 through the lysosome pathway mediated by Cathepsin B, exerting activities such as inhibiting tumor cell proliferation, migration, and invasion. HDAC3-IN-7 is promising for research of cancers.
    HDAC3-IN-7
  • HY-P991348
    BAT-1306
    		Inhibitor
    BAT-1306 is a human monoclonal antibody (mAb) targeting PDCD1/PD-1/CD279. BAT-1306 can be used in Colorectal cancer and Solid tumours research.
    BAT-1306
  • HY-162973
    PD-L1 ligand 1
    		Degrader
    PD-L1 ligand 1 is a PROTAC target protein ligand. PD-L1 ligand 1 can be used as a PD-L1 degrader.
    PD-L1 ligand 1
  • HY-B1387R
    Sulfamethoxypyridazine (Standard)
    		Inhibitor
    Sulfamethoxypyridazine (Standard) is the analytical standard of Sulfamethoxypyridazine. This product is intended for research and analytical applications. 0
    Sulfamethoxypyridazine (Standard)
  • HY-P991079
    Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
    		Inhibitor
    Anti-Mouse PD-1 Antibody (D265A) Antibody is a mouse-derived IgG2a, κ type antibody inhibitor, targeting to mouse PD-1.
    Anti-Mouse PD-1 Antibody (D265A) Antibody (RMP1-14)
Cat. No. Product Name / Synonyms Application Reactivity